This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those sold over the counter. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy.

The goal of this guide is to review the literature on treating substance misuse and substance use disorders in the context of first-episode psychosis, distill the research into recommendations for practice, and provide examples of the ways that these recommendations can be implemented by first-episode psychosis treatment programs.

This guide examines a wide range of evidence-based practices for screening and assessment of people in the justice system who have co-occurring mental and substance use disorders.

Zero Suicide operationalizes the core components necessary for health care systems to transform suicide care into seven elements. Within each element section, find a description of what each element is, why it is necessary to Zero Suicide implementation, a summary of supporting research, and key readings and tools. Use the navigation bar that appears at the top of each element page to jump between sections.

This guide discusses the challenges in care transitions and the need for better care practices and care coordination from inpatient to outpatient behavioral health care, and presents feasible, evidence-based practices that health systems and providers can take to improve patient connection and safety during inpatient to outpatient transition, and provides recommendations specific to both inpatient and outpatient settings.